Simple jQuery Dropdowns
Please use this identifier to cite or link to this item: http://repository.li.mahidol.ac.th/dspace/handle/123456789/12405
Full metadata record
DC FieldValueLanguage
dc.contributor.authorPrasert Thongcharoenen_US
dc.contributor.authorPrasert Auewarakulen_US
dc.contributor.authorYanee Hutagalungen_US
dc.contributor.authorGary Ongen_US
dc.contributor.authorPaul Gillarden_US
dc.contributor.authorMamadou Drameen_US
dc.contributor.authorHans L. Bocken_US
dc.contributor.otherMahidol Universityen_US
dc.contributor.otherGlaxoSmithKlineen_US
dc.date.accessioned2018-05-03T08:28:22Z-
dc.date.available2018-05-03T08:28:22Z-
dc.date.issued2011-08-01en_US
dc.identifier.citationJournal of the Medical Association of Thailand. Vol.94, No.8 (2011), 916-926en_US
dc.identifier.issn01252208en_US
dc.identifier.other2-s2.0-79961186873en_US
dc.identifier.urihttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=79961186873&origin=inwarden_US
dc.identifier.urihttp://repository.li.mahidol.ac.th/dspace/handle/123456789/12405-
dc.description.abstractObjective: The present study (NCT00449670) in Asian subjects (18-60 years) evaluated the manufacturing consistency of four formulations of 3.75mg AS03 A -adjuvanted H5N1 influenza vaccine, in terms of post-immunization Hemagglutination Inhibition (HI) titers against the A/Vietnam/1194/2004 and A/Indonesia/05/2005 strains. The immunogenicity and safety of the vaccine in the Thai population are reported herein. Material and Method: Subjects were randomized (2:2:2:2:1:1) between four vaccine groups and two control groups to receive two doses of either the AS03 A -adjuvanted or non-adjuvanted H5N1 vaccine formulations, 21 days apart. Sera were assayed for HI antibody titers against the two strains. Results: After the second dose of AS03 A -adjuvanted vaccine, 94.2% subjects in the H5N1-AS03 A groups seroconverted and 94.9% subjects were seroprotected against the A/Vietnam/1194/2004 strain. Cross-clade immune response against the A/Indonesia/05/2005 strain was observed. All vaccine formulations had an acceptable safety profile. Conclusion: This antigen-sparing AS03 A -adjuvanted influenza vaccine could be a suitable candidate for combating and mitigating future influenza pandemics.en_US
dc.rightsMahidol Universityen_US
dc.source.urihttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=79961186873&origin=inwarden_US
dc.subjectMedicineen_US
dc.titleCross-clade immunogenicity and antigen-sparing with an AS03<inf>A</inf>-adjuvanted prepandemic influenza vaccine in a Thai populationen_US
dc.typeArticleen_US
dc.rights.holderSCOPUSen_US
Appears in Collections:Scopus 2011-2015

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.